We are a biopharmaceutical company focused on the discovery, development and
commercialization of small molecule drugs for the treatment of central nervous
system disorders. We currently have four drug programs in clinical development
and several additional programs in preclinical and discovery stages. Our three
Phase II clinical programs are ACP-103 for treatment-induced dysfunctions in
Parkinson’s disease, ACP-103 as an adjunctive therapy for schizophrenia, and
ACP-104 for the treatment of schizophrenia. We have retained worldwide
commercialization rights for these programs. We also have a neuropathic pain
program in Phase I clinical trials and a glaucoma program in preclinical
development, each in collaboration with Allergan, Inc. Using our proprietary
drug discovery platform, we have discovered all of the drug candidates in our
product pipeline.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f18%2f0001193125-05-055069.html#FIS_BUSINESS"